How Does ALUNBRIG® (brigatinib) Work?
Getting Started on Once-Daily ALUNBRIG®
You may have some questions about your treatment. This site was designed to help you understand how ALUNBRIG works.
Don’t Forget...
Before starting ALUNBRIG, tell your healthcare provider about all medical conditions you have and medications you are taking, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.
How Does Once-Daily ALUNBRIG Work?
- ALUNBRIG works by blocking the abnormal ALK protein responsible for the growth and spread of ALK+ NSCLC
ALUNBRIG Was Shown to Shrink Tumors After Crizotinib Treatment
The ALUNBRIG study included 222 people with ALK+ NSCLC whose cancer had spread to other parts of the body and who had taken the medicine crizotinib and their disease worsened. One hundred ten patients received the recommended dosing regimen of 90 mg of ALUNBRIG orally once daily for 7 days, followed by an increase to 180 mg orally once daily (90180-mg group).
Study Results for the Recommended Dosing Regimen Group
53% (58 out of 110) of patients achieved a response, meaning that their tumors either shrank or disappeared while taking ALUNBRIG.
- 5 out of 110 (4.5%) patients achieved a complete response
- 53 out of 110 (48%) patients achieved a partial response
Additional Study Results
In the same study, 112 patients received 90 mg of ALUNBRIG orally once daily (90-mg group) without having their dose increased.
- 54 out of 112 (48%) patients achieved a response
- 4 out of 112 (3.6%) patients achieved a complete response
- 50 out of 112 (45%) patients achieved a partial response
Responses lasted a median of 13.8 months in both dosing groups
Glossary
- Median
- A median is the middle number in a set of data. In other words, half of the numbers in the group are more than the median and half of the numbers in the group are less than the median.
- Complete response
- The disappearance of tumors in response to a given treatment. This is not the same as a cure.
- Partial response
- The decrease in the size and spread of tumors in response to a given treatment.
ALUNBRIG Also Showed Results in the Brain
Study Results for the Recommended Dosing Regimen Group
In the same study, 18 patients in the 90180-mg group had measurable tumors that had spread to the brain
Brain tumors shrank in two-thirds of patients (12 out of 18)
- Zero patients had a complete response in the brain
- 12 out of 18 (67%) patients had a partial response in the brain
Additional Study Results
In 26 patients with ALK+ NSCLC in the 90-mg group who had measurable tumors that had spread to the brain
Brain tumor responses lasted a median DURATION of nearly 6 months with the recommended dosing regimen
Brain tumors shrank in 11 out of 26 (42%) patients
- 2 out of 26 (7.7%) patients had a complete response in the brain
- 9 out of 26 (35%) patients had a partial response in the brain
- The median duration of brain tumor responses could not be determined in this group
Among the 23 patients who responded to treatment, 78% of patients in the 90-mg group and 68% of patients in the 90180-mg group kept responding to treatment for at least 4 months.